Come with me,” Koenigsegg Jesko buyer Bilal Hydrie said over the phone. “This will be a once-in-a-lifetime experience.” ...

500HP Alpine A110 Pikes Peak Monster – Turbo Anti-Lag, Brutal Sounds & Hillclimb Action Posted: May 17, 2025 | Last updated: May 17, 2025 Watch the 500HP Alpine A110 Pikes Peak edition attack ...

Get up close with a true modern supercar: this 1000HP BMW M4 G82 features a monstrous single turbo upgrade, delivering jaw-dropping performance. Watch as it unleashes brutal anti-lag, throws down ...

Curious about the fastest Ford trucks ever built? Check out six high-performance models that combined power, speed, and ...

Clinical activity of immune checkpoint blockade in advanced perivascular epithelioid cell neoplasms (PEComas): A retrospective single center study. Comprehensive molecular analysis of phase IB/II ...

NivoReach: Integrated study to demonstrate similarity of JPB898 to reference nivolumab in combination with ipilimumab in patients with advanced melanoma. This is an ASCO Meeting Abstract from the 2025 ...

Rolling Stone may receive an affiliate commission. Huckberry just released a limited-edition workwear collection with Ford, and it’s making us want to go full Americana this summer — à la ...

According to Wood Mackenzie, the gas turbine market could face "turbo lag" from 2025-2040 due to rising costs, manufacturing constraints and competition from renewables. WoodMac notes that global ...

Rather than the buzzy, motorsport-bred, Cosworth-tuned engine from the original, this tribute packs a rather blasphemous 3.0-liter, twin-turbocharged V6 from a Ford F-150 Raptor. It naturally ...

Harrison Ford may have played a role in the creative direction of Something Beautiful. In a new interview for The Zane Lowe Show on Apple Music 1, Miley Cyrus shared that the iconic actor made a ...

The nation’s most influential anti-abortion groups have a new plan ... The effort, which the groups have privately named “Rolling Thunder,” is the movement’s first concerted attempt ...

MSD has decided to abandon the development of its anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline. The demise of the two ...